Sara Barrias, a researcher at UTAD, has won the Innovation Award from the Portuguese League Against Cancer for her groundbreaking work on an innovative biosensor designed for the rapid detection of a BRCA2 gene mutation linked to hereditary breast cancer.
The technology, as explained by the university, utilizes liquid biopsies, allowing for the identification of the Portuguese founder mutation in this gene in a less invasive, more accessible manner with potential clinical application.
In the university’s statement, Sara Barrias emphasized “the clinical potential of the study, particularly in breast cancer prevention.”
The researcher expressed feeling “recognized and privileged” by the award, noting that it “will boost the project, particularly through the acquisition of new materials and equipment optimization.”
“This support will be crucial for the advancement of research,” she added.
The award comprises financial support of €7,500, granted by BioPortugal, recognizing pioneering projects in oncology.
“In addition to early detection, the tool could be applied in monitoring disease progression, tracking treatment responses, and facilitating faster and more effective clinical decisions,” the university further noted.
Breast cancer is the most frequently diagnosed cancer among women worldwide, with approximately 5 to 10% of cases having a hereditary origin linked to mutations in the BRCA1 and BRCA2 genes.
The research at UTAD aims to “offer an innovative response to this public health challenge.”
The award was presented on Wednesday in Porto during the 7th National Meeting of Young Researchers in Oncology, which showcased around 90 research projects nationwide.
For UTAD, this recognition confirms the significance of the scientific work carried out by its researchers and strengthens the university’s commitment to innovation and knowledge transfer in the fields of molecular genetics and medicine, conducted at the Genetics4U Laboratory for the benefit of society.
